BioHarvest Sciences Overview
Latest ROE for BioHarvest Sciences: -56.03% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-56.03%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for BHST is -56.03%. That is below the sector sector average of 11.75%. Investors often review this figure alongside BioHarvest Sciences's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, BHST currently prints -56.03% for ROE, while the sector average sits near 11.75%. That is roughly 576.6% below the sector mean. Large gaps often invite a closer look at BioHarvest Sciences's growth, margins, and balance sheet.
Return on Equity shows how effectively BioHarvest Sciences converts resources into returns. At -56.03%, BHST may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting BHST's ROE (-56.03%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
